3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NIH
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
196
Myelodysplastic Syndromes
128
Precursor Cell Lymphoblastic Leukemia-Lymphoma
123
Leukemia, Lymphocytic, Chronic, B-Cell
102
Leukemia
102
Lymphoma
86
Multiple Myeloma
81
Lymphoma, Non-Hodgkin
80
Hematologic Neoplasms
65
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
62
Hodgkin Disease
62
Recurrence
52
Lymphoma, B-Cell
40
Lymphoma, Mantle-Cell
39
Myeloproliferative Disorders
36
Lymphoma, Follicular
35
Melanoma
34
Lymphoma, Large B-Cell, Diffuse
31
Burkitt Lymphoma
31
Graft vs Host Disease
28
Neoplasms, Plasma Cell
24
Primary Myelofibrosis
23
Ovarian Neoplasms
23
Lymphoma, B-Cell, Marginal Zone
23
Anemia, Refractory, with Excess of Blasts
21
Leukemia, Myelomonocytic, Chronic
20
Leukemia, Biphenotypic, Acute
17
Lymphoma, T-Cell
16
Neuroblastoma
15
Neoplasms
14
Interventions
Oxaliplatin
180
Capecitabine
174
Fluorouracil
154
Radiotherapy
107
Leucovorin
107
Irinotecan
93
Bevacizumab
69
Surgical Procedures, Operative
49
Cetuximab
39
Drug Therapy
38
Radiation
35
Neoadjuvant Therapy
33
Folfox protocol
29
Chemoradiotherapy
29
XELOX
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
21
Radiotherapy, Intensity-Modulated
19
Surveys and Questionnaires
17
Proctectomy
16
Biopsy
16
Early Intervention, Educational
14
trifluridine tipiracil drug combination
12
Panitumumab
12
Floxuridine
12
tislelizumab
11
regorafenib
11
Nivolumab
11
Laparoscopy
11
Celecoxib
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Rectal Neoplasms
×
fludarabine
×
Clear all
NCT06530303
2024-11-05
BAH248
Essen Biotech
Phase 1/2
Recruiting
85 enrolled